Bicyclo Patents (Class 514/756)
-
Patent number: 12150921Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.Type: GrantFiled: June 14, 2023Date of Patent: November 26, 2024Assignee: Bryn Pharma, LLCInventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
-
Patent number: 11000489Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.Type: GrantFiled: July 16, 2020Date of Patent: May 11, 2021Assignee: Bryn Pharma, LLCInventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
-
Patent number: 10925841Abstract: Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.Type: GrantFiled: May 1, 2020Date of Patent: February 23, 2021Assignee: Bryn Pharma, LLCInventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
-
Patent number: 10464887Abstract: The present invention provides a method for producing an active ingredient for a rivastigmine free base transdermal patch having preparing a rivastigmine free base; and adding an acidic substance to the rivastigmine free base and subjecting the acidic substance and the rivastigmine free base to a mixed reaction to form a mixture having a pH value from 6.0 to 8.5 as the active ingredient; and a rivastigmine free base transdermal patch having a drug layer comprising the active ingredient. The rivastigmine free base transdermal patch has a stable transdermal transmission time equal to or longer than 48 hours and equal to or less than 168 hours. The active ingredient produced by the method and the transdermal patch having the active ingredient allow effective and smooth release of rivastigmine free base and prolongs the release time to meet the clinical application needs.Type: GrantFiled: December 14, 2017Date of Patent: November 5, 2019Inventor: Tsung-Min Hsu
-
Patent number: 9999590Abstract: The subject invention provides improved diclofenac gel formulations.Type: GrantFiled: July 4, 2013Date of Patent: June 19, 2018Assignee: Ferring B.V.Inventors: Arnaud Grenier, Dario N. Carrara
-
Patent number: 9949935Abstract: Rivastigmine transdermal compositions are provided. Aspects of the transdermal compositions include an active agent layer which includes rivastigmine and a solubility modulator, e.g., crosslinked acrylic acid polymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.Type: GrantFiled: March 23, 2015Date of Patent: April 24, 2018Assignee: Teikoku Pharma USA, Inc.Inventor: Kensuke Murata
-
Publication number: 20150126476Abstract: The present invention relates to the use of topical compositions containing bromociclen for the prevention and/or treatment of various types of dermatitis, in particular eczema and psoriasis.Type: ApplicationFiled: January 2, 2015Publication date: May 7, 2015Inventor: Carmelo Cutrupi
-
Patent number: 8729092Abstract: The invention discloses a method for the treatment of diseases, particularly those diseases characterized by diminished or aberrant cellular function, including AIDS, cancer, and Alzheimer's Disease. The method comprises administering a therapeutically effective amount of rosuvastatin enantiomer compounds in their (3R,5R), (3S,5R), or (3S,5S) configurations, or pharmaceutically acceptable salts thereof. Biologically-active rosuvastatin enantiomer compounds with (3R,5R), (3S,5R), and (3S,5S) stereochemistry are also disclosed.Type: GrantFiled: September 24, 2012Date of Patent: May 20, 2014Inventor: Terence J. Scallen
-
Patent number: 8673984Abstract: Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene oxide) block copolymer. These stabilized perfluorocarbon emulsions can be used in liquid and/or hydrogel phases of perfusion bioreactors or various other culture systems to enhance cell viability in thick tissue constructs, or as blood substitutes, although other applications may also be considered.Type: GrantFiled: December 8, 2009Date of Patent: March 18, 2014Assignee: University of Utah Research FoundationInventors: Natalya Y. Rapoport, Glenn D. Prestwich, Russell Morris Condie
-
Publication number: 20120225102Abstract: A perfluorocarbon gel composition is disclosed with numerous uses including topical medical and cosmetic uses.Type: ApplicationFiled: April 16, 2012Publication date: September 6, 2012Inventors: Gerald Klein, Richard Kiral, Chris J. Stern
-
Publication number: 20110223243Abstract: The invention relates to dispersions of artificial oxygen carriers, wherein the dispersions contain capsules with reversible oxygen storage capacity, the capsules comprising an oxygen-permeable capsule material, that contains and/or encloses fluorinated, particularly perfluorinated hydrocarbons, preferably perfluorocarbons. The dispersions are particularly suitable as a blood substitute, preferably for the purpose of transfusion, e.g. in states of blood loss of the human or animal body, in particular following surgical interventions, accidents, injuries etc, or for the prophylactic treatment and/or treatment by therapy of ischaemic states or states following a reperfusion.Type: ApplicationFiled: July 8, 2009Publication date: September 15, 2011Inventors: Herbert De Groot, Christian Mayer, Frank Petrat, Michael Kirsch
-
Publication number: 20110027384Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.Type: ApplicationFiled: April 6, 2009Publication date: February 3, 2011Applicant: National University of SingaporeInventors: Anil Kishen, Saji George
-
Publication number: 20100267842Abstract: The subject application provides for an emulsion comprising an amount of a perfluorocarbon liquid dispersed as particles within, a continuous liquid phase, wherein the dispersed particles have a monomodal particle size distribution and uses thereof. The subject application also provides for a method of manufacturing a perfluorocarbon emulsion, a process for preparing a pharmaceutical product containing a PFC emulsion and a process for validating a batch of an emulsion for pharmaceutical use.Type: ApplicationFiled: April 15, 2010Publication date: October 21, 2010Inventors: Richard Kiral, Deborah P. Thompson, Gary L. Clauson
-
Patent number: 7488854Abstract: The present invention provites a compound having the following structure: wherein, in the formula: X is selected from the group consisting of hydroxy, substituted hydroxy, halogen, thiol, and substituted thiol; one of Y1 and Y2 is hydrogen or alkyl, and the other is Z-W, wherein Z is a single bond, or a divalent group having alkane or substituted alkane having two hydrogen atoms removed, and W is hydroxy, substituted hydroxy, aldehyde, carboxyl, or substituted carboxyl; and R1-R24 are independently selected from the group of hydrogen, alkyl, and substituted alkyl.Type: GrantFiled: March 12, 2003Date of Patent: February 10, 2009Assignees: The National Institute of Agrobiological Sciences, RikenInventors: Shigemi Seo, Yuko Ohashi, Hideharu Seto, Shigeo Yoshida
-
Publication number: 20080075710Abstract: An herbal composition is adapted to treat hangovers. In one embodiment, the herbal composition comprises potassium, thiamin (vitamin B-1), magnesium, silymarin and N-acetyl-L-cysteine (acetylcysteine), or any pharmaceutically acceptable salts thereof. In a method of treating hangovers, an herbal composition is provided that comprises potassium, thiamin, magnesium, silymarin and N-acetyl-L-cysteine. The herbal composition is placed in the body so as to alleviate or reduce the effects of a hangover.Type: ApplicationFiled: September 11, 2007Publication date: March 27, 2008Inventors: Erik T. Cornett, Gerad A. Harsy
-
Patent number: 7252845Abstract: Novel compositions of matter containing aromatic compounds and terpenoids which are present in and may preferably be derived from the plant Alpinia galanga (Zingiberaceae) show synergistic effects with respect to immunomodulation, and they significantly suppress hypersensitivity reactions. Thus they are used for preparing medicaments for these purposes and, more specifically, for the treatment or prevention of IgE mediated allergic reactions and conditions, such as asthma, allergic rhinitis, atopic eczema or anaphylaxis, and autoimmune disorders, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis or psoriasis, as well as for the alleviation of pain. They can for example be formulated into pharmaceuticals, cosmetics or dietary supplements. A method of preparing such compositions from Alpinia galanga is also described.Type: GrantFiled: January 2, 2003Date of Patent: August 7, 2007Assignee: Ferrosan A/SInventors: Morten Sloth Weidner, Morten Just Petersen, Nina Worm Jensen
-
Publication number: 20040266889Abstract: A method of forming an end seal (50) for a manufactured seed (22) is provided. The method includes providing a manufactured seed having an open-end (56) and immersing at least the open end of the manufactured seed in a sealing material (54) for a predetermined period of time. The method also includes permitting the sealing material to harden over the opened end of the manufactured seed to form a plug that seals the opened end.Type: ApplicationFiled: May 24, 2004Publication date: December 30, 2004Inventor: Edwin Hirahara
-
Patent number: 6444700Abstract: In its broadest aspect, the present invention is directed to the discovery of immunonutritional products that are useful in reducing the immunological system suppression that results from stress. The stress may be in the form of physical exertion, mental exhaustion, disease states and the like. In one embodiment, the invention relates to a nutritional composition comprising a structured glyceride component and an antioxidant system. This nutritional composition has been shown to be highly effective in reducing immune system down regulation or dysregulation as a result of stress.Type: GrantFiled: March 19, 2001Date of Patent: September 3, 2002Assignee: Abbott LaboratoriesInventors: Stephen J. DeMichele, John W. McEwen, Steven M. Wood
-
Patent number: 6337337Abstract: A method for treating disorders responsive to DHFR inhibition is disclosed, wherein the disorders may include neoplastic diseases, rheumatoid arthritis, restenosis, multiple sclerosis, lupus, infections, and ectopic pregnancy. The inventive method comprises administering to a patient in need of treatment a therapeutically-effective amount of a composition comprising certain aromatic, primarily non-aliphatic, molecules that may be found in coal tar.Type: GrantFiled: September 3, 1999Date of Patent: January 8, 2002Inventor: Carol J. Buck
-
Patent number: 6235796Abstract: Method for the prevention and inhibition of adhesion between tissues comprising the use of fluorocarbons are disclosed. The method provides for the introduction of a fluorocarbon into the surgical site of a mammalian body, such as a human, to minimize friction and enhance the mobility of the surrounding tissues and organs. The fluorocarbons introduced may be in various forms including liquid and emulsions, and provides a coating, film or barrier thereby reducing the surface tension associated after surgery. The subject invention further discloses the use of perfluorodecalin as a preferred fluorocarbon compound used as the primary anti-adhesion agent.Type: GrantFiled: June 26, 2000Date of Patent: May 22, 2001Inventor: Sarfaraz K. Niazi
-
Patent number: 5859068Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.Type: GrantFiled: February 24, 1995Date of Patent: January 12, 1999Assignee: Children's Medical Center CorporationInventor: Jay M. Wilson
-
Patent number: 5824703Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.Type: GrantFiled: December 27, 1996Date of Patent: October 20, 1998Assignee: Synthetic Blood International, Inc.Inventor: Leland C. Clark, Jr.
-
Patent number: 5684050Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.Type: GrantFiled: May 15, 1995Date of Patent: November 4, 1997Assignee: HemaGen/PFCInventors: Leland C. Clark, Jr., Robert Francis Shaw
-
Patent number: 5674913Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung or hyperinflated lung syndrome, and instilling a perfluorochemical liquid into the trachea for administration in the alveolar sacs of a lung of the animal. The perfluorochemical is permeable to the ambient gas and resides substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. In another aspect of the invention, the method further includes the step of alleviating the lung disorder without inducing hyperinflated lung syndrome.Type: GrantFiled: May 13, 1994Date of Patent: October 7, 1997Assignee: Synthetic Blood International, Inc.Inventor: Leland C. Clark, Jr.
-
Patent number: 5635539Abstract: Stable emulsions of highly fluorinated organic compounds for use as oxygen transport agents, "artificial bloods" or red blood cell substitutes and as contrast agents for biological imaging. The emulsions comprise a highly fluorinated organic compound, an oil that is not substantially surface active and not significantly soluble in water, a surfactant and water.Type: GrantFiled: May 23, 1996Date of Patent: June 3, 1997Assignee: HemaGen/PFCInventors: Leland C. Clark, Jr., Robert F. Shaw
-
Patent number: 5573757Abstract: Compositions for topical application in gel form comprising a fluorocarbon or perfluorocarbon compound or mixtures thereof at a concentration of at least about 75% v/v, a minor quantity of a surface active agent and an aqueous phase.The compositions provide a storage-stable high concentration fluorocarbon gel that is prepared without the use of thickeners or additional stabilizing agents. The gels are useful in formulations for pharmaceutical, cosmetic purposes and for other products as well.Type: GrantFiled: October 3, 1994Date of Patent: November 12, 1996Assignee: Alliance Pharmaceutical Corp.Inventors: Jean G. Riess, Marie-Pierre Krafft
-
Patent number: 5565460Abstract: The present invention relates to a therapeutic agent for Parkinson's disease containing as an active ingredient a polycyclic compound or a pharmaceutically acceptable salt thereof, the compound being represented by the following Formula (I): ##STR1## and A represents N or CR.sup.5 (in which R.sup.5 represents hydrogen, or substituted or unsubstituted lower alkyl), or represented by the following Formula (II): ##STR2## wherein Y, R.sup.6 and R.sup.8 are as defined herein and B and the adjacent two carbon atoms are combined to form a substituted or unsubstituted, partially saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic group.Type: GrantFiled: March 3, 1995Date of Patent: October 15, 1996Assignee: Kyowa Hakko Koygo Co., Ltd.Inventors: Fumio Suzuki, Junichi Shimada, Nobuaki Koike, Shunji Ichikawa, Joji Nakamura, Tomoyuki Kanda, Shigeto Kitamura
-
Patent number: 5374624Abstract: The present invention relates to fluorochemical blood substitutes used for preserving mammalian tissue having lysophosphatidyl compounds in non-toxic concentrations. More specifically, the invention relates to aqueous fluorochemical emulsions of a fluorochemical and an emulsifier useful as oxygen delivery agents and methods of preserving tissue in investigational and clinical settings, particularly those settings involving in in vivo transfusion, cardiac and other organ preservation, and in vitro organ perfusion.Type: GrantFiled: August 11, 1993Date of Patent: December 20, 1994Inventor: Leigh D. Segel
-
Patent number: 5270345Abstract: Novel pesticidal compositions, which are characterized by biodegradability and do not bioaccumulate to an unacceptable level in fats and tissues of animals, fowl and fish, containing active compounds and optionally a carrier suitable for administering said compounds to a pest by contact, ingestion or inhalation, are disclosed. Such compositions comprise in addition to the carrier compounds of the formula ##STR1## where R is H, Cl or other Hal, hydroxyl, lower alkoxyl, lower alkyl, cyano, CONR.sub.2 or NR.sub.2 where R.sub.Type: GrantFiled: May 3, 1991Date of Patent: December 14, 1993Assignee: Coulston International CorporationInventor: Frederick Coulston
-
Patent number: 5104900Abstract: A new use for naphthalene comprising a snake repellant in the form of granules comprising 8% naphthalene, 32% sulfur and 60% montmorillonite. The compound is spread in a strip across an area where snakes are to be repelled and is effective against venomous and non-venomous varieties.Type: GrantFiled: February 28, 1990Date of Patent: April 14, 1992Inventor: James B. Tennyson
-
Patent number: 5073383Abstract: Aggregation of fluorocarbon emulsion particles, which occurs when the emulsion mixes with blood, is reduced by the addition of relatively large amounts of phosphate.Type: GrantFiled: April 21, 1989Date of Patent: December 17, 1991Assignee: Affinity Biotech, Inc.Inventor: Robert T. Lyons
-
Patent number: 5061484Abstract: A stable perfluorochemical emulsion is provided which comprises perfluorochemical particles in stabilized vesicles. The vesicles comprise a biocompatible polymer formed by coating the perfluorochemical particles with one or more phospholipid monomer(s) and polymerizing the monomer(s).Type: GrantFiled: March 10, 1989Date of Patent: October 29, 1991Assignee: Alpha Therapeutic CorporationInventor: Charles M. Heldebrant
-
Patent number: 4917930Abstract: Compositions having enhanced gas and drug transporting capability, are prepared by providing a perfluoro compound dispersed in an aqueous medium with a surfactant to form an aqueous initial dispersion, concentrating the perfluoro compound phase of the dispersion as by centrifugation or filtration, wherein a portion of the surfactant remains complexed with the particles of the perfluoro compound phase and the balance of the surfactant is in the aqueous phase, separating the phases, and redispersing the particles of the concentrated perfluoro compound phase to form a final dispersion in which greater than 65% by weight, and preferably at least 75%, of the surfactant present is complexed with the perfluoro compound particles.Type: GrantFiled: October 3, 1986Date of Patent: April 17, 1990Assignee: Adamantech, Inc.Inventor: William McCormick
-
Patent number: 4895876Abstract: A stable concentrated aqueous emulsion of perfluorochemical, a phospholipid and a triglyceride of fatty acids has been demonstrated which has enhanced stability, diminished particle size and heightened tolerance by biological systems. The emulsion has utility as an oxygen transport medium, such as artificial blood. The emulsion can optionally include additional emulsifiers of SURFYNOL.RTM.SE surfactant and PLURONIC.RTM. P-105 surfactant. The emulsion is produced using an improved emulsification technique. The invention includes methods of oxygen transport in vascular systems wherein the oxygen carrying capacity of the vascular systems is improved with the emulsions of the present invention. Methods are also described for organ preservation extra-vivo by perfusing, suffusing, flushing and filling organs outside the body with the oxygen carrying emulsions of the present invention.Type: GrantFiled: March 20, 1987Date of Patent: January 23, 1990Assignee: Air Products and Chemicals, Inc.Inventors: Frank K. Schweighardt, Charles R. Kayhart
-
Patent number: 4879062Abstract: An inert, water-immiscible inert organic liquid having gas transport properties, water and a suitable emulsifying agent are formed into a stable gel by emulsifying a mixture of the same, concentrating the emulsion to form a gel phase and a liquid phase and separating the two phases. The resulting gel can be used as an ointment or cosmetic for skin irritations or wounds, or as a coating in industrial applications where extended contact of a surface with a gas, such as oxygen, is desired. Fluorocarbons or low viscosity silicone oils are suitable organic liquid components of the gels.Type: GrantFiled: September 19, 1985Date of Patent: November 7, 1989Assignee: Adamantech, Inc.Inventor: Robert E. Moore
-
Patent number: 4866096Abstract: A stable aqueous emulsion of perfluorochemical, a phospholipid and a triglyceride of fatty acids has been demonstrated which has enhanced stability, diminished particle size and heightened tolerance by biological systems. The emulsion has utility as an oxygen transport medium, such as artificial blood.Type: GrantFiled: March 20, 1987Date of Patent: September 12, 1989Assignee: Air Products and Chemicals, Inc.Inventor: Frank K. Schweighardt
-
Patent number: 4569943Abstract: The compound of the formula: ##STR1## wherein R.sub.1 is hydrogen, methyl or hydroxymethyl, R.sub.2 is hydrogen or methoxy, R.sub.3 is hydroxy or methoxy, and R.sub.4 is hydrogen or a group ##STR2## is novel, and the compound is of use as inhibitors of animal tissue fibrosis, or biochemical reagents.Type: GrantFiled: October 19, 1983Date of Patent: February 11, 1986Assignee: Takeda Chemical Industries, Ltd.Inventors: Hisayoshi Okazaki, Kazuhiko Ohta, Takenori Ishimaru
-
Patent number: 4497829Abstract: Particles of perfluoro compound with a lipid coating are emulsified by sonification in aqueous medium, wherein the proportion of perfluoro compound in the emulsion is preferably about 30-75% (w/v) and the proportion of lipid is preferably about 7-9% (w/v). In the resulting stable emulsion 95% of these particles having diameters less than 0.2.mu.. The emulsion is useful as an artificial blood for transport and delivery of oxygen to body tissues.Type: GrantFiled: August 19, 1983Date of Patent: February 5, 1985Assignee: The University of PennsylvaniaInventor: Henry A. Sloviter